Multiple Myeloma section

Multiple Myeloma News & Features

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

The 18-month progression-free survival rate was 71.6% among patients treated with daratumumab plus VMP compared with 50.2% among patients treated with VMP alone.

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

In this phase 2 study, 38 patients with previously untreated multiple myeloma who were ineligible for autologous stem cell transplantation were treated with a bortezomib-containing induction regimen until plateau.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs